Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical efficacy of switching to 2nd generation of tyrosine kinase inhibitor on CML patients at poor responses to imatinib].

Zhongguo shi yan xue ye xue za zhi - 1 Feb 2015

Qiao Jian-Hui, Zhang Ze-Chuan, Yao Bo, Li Bing-Xia, Guo Mei, Sun Qi-Yun, Hu Kai-Xun, Yu Chang-Lin, Dong Zheng, Ai Hui-Sheng

Abstract excerpt

OBJECTIVE: This study was to investigate the timing and clinical efficacy of switching to the 2nd generation of tyrosine kinase inhibitor (TKI) for CML patients at poor response to imatinib (dissatifed efficacy or intolerance). METHODS: The therapeatic efficacy and side reaction of switched 2nd TKI in patients with newly diagnsed CML-CP who poorly responded to imatinib were observed, anong them 3 cases were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Blast Crisis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytogenetics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Pleural Effusion

Share to Remission Induction

Source

Identifiers

PMID: 25687048
DOI: 10.7534/j.issn.1009-2137.2015.01.013

Genes

BCR
ELN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical efficacy of switching to 2nd generation of tyrosine kinase inhibitor on CML patients at poor responses to imatinib].PMID 25687048Read ↗

[Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia--Review].Semantic proximity Read ↗

[Key points in second-line therapy for chronic myeloid leukemia].Semantic proximity Read ↗

A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.Semantic proximity Read ↗

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?Semantic proximity Read ↗

Long-term outcome of Tyrosine Kinase Inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase: A single-center experience in ChinaSemantic proximity Read ↗

[Clinical Analysis for 42 Imatinib-resistant Patients with Chronic Myelogenous Leukemia].Semantic proximity Read ↗

The impact of pretransplant use of tyrosine kinase inhibitors on allogeneic stem cell transplantation in patients with chronic myeloid leukemia - A single-institution retrospective studySemantic proximity Read ↗

Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.Semantic proximity Read ↗

[Origin of resistance to Imatinib mesylate: lessons learned from this experience].Semantic proximity Read ↗

[The efficacy analysis of interferon combined with imatinib in chronic myelogenous leukemia patients with ABL kinase domain mutations].Semantic proximity Read ↗

[Application of imatinib in BCR- ABL positive acute lymphoblastic leukemia treatment in the real world].Semantic proximity Read ↗

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.